Page last updated: 2024-09-05

cilengitide and Brain Neoplasms

cilengitide has been researched along with Brain Neoplasms in 48 studies

Research

Studies (48)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	8 (16.67)	29.6817
2010's	39 (81.25)	24.3611
2020's	1 (2.08)	2.80

Authors

Authors	Studies
Alalami, H; Bannykh, S; Fan, X; Hu, J	1
Camargo, MF; Cheresh, DA; Chneiweiss, H; Cosset, É; Dietrich, PY; Dutoit, V; Elliott, K; Gomez, G; Guan, KL; Ilmjärv, S; Krause, KH; Mischel, PS; Moo, JS; Moroishi, T; Preynat-Seauve, O; Reiss, A; Sarkaria, JN; Seguin, L; von Schalscha, T; Weis, SM	1
Date, I; Ichikawa, T; Ishida, J; Kurozumi, K	1
Chen, X; Ma, W; Wang, J; Yan, C; Yang, Y	1
An, X; Ge, H; Gu, T; Guo, L; Jiang, Q; Meng, X; Ning, X; Shan, X; Zhang, L	1
Chiocca, EA; Date, I; Fujii, K; Ichikawa, T; Ishida, J; Kaur, B; Kurozumi, K; Onishi, M; Shimazu, Y	1
Chen, L; Gajjar, A; Kieran, MW; MacDonald, TJ; Pierson, CR; Pollack, IF; Stewart, CF; Turner, D; Vezina, G	1
Chakravarti, A; Huebner, A; Ibrahim, A; Lautenschlaeger, T; Li, B; Meng, W; Peereboom, D; Perry, J; White, J	1
Date, I; Ichikawa, T; Kurozumi, K; Onishi, M	2
Homicsko, K; Hottinger, AF; Stupp, R	1
Clément, PM; Eisele, AC; Eisele, G; Krex, D; Neyns, B; Nikkhah, G; Ochsenbein, A; Picard, M; Schlegel, U; Simon, M; Stupp, R; Tabatabai, G; Tonn, J; Weller, M; Wick, A; Wick, W	1
Bertram, A; Hendruschk, S; Kirsch, M; Liebner, C; Lord, EM; Martin, DK; Schackert, G; Sitoci-Ficici, KH; Temme, A; Uckermann, O	1
Chinot, OL	1
Adamska, K; Aldape, KD; Brandes, AA; Erridge, SC; Gorlia, T; Grujicic, D; Gupta, T; Hau, P; Hegi, ME; Herrlinger, U; Hicking, C; Hong, YK; Kim, CY; Kortmann, RD; Lhermitte, B; Markivskyy, A; McBain, C; Nabors, LB; Nam, DH; Perry, J; Picard, M; Pietsch, T; Rao, N; Reardon, DA; Schnell, O; Shen, CC; Steinbach, JP; Stupp, R; Taphoorn, MJ; Tarnawski, R; Thurzo, L; Tonn, JC; van den Bent, MJ; Weller, M; Weyerbrock, A; Wick, W; Wiegel, T	1
Ameratunga, MS; Grant, R; Khasraw, M; Pavlakis, N; Wheeler, H	1
Doostkam, S; Machein, MR; Plate, K; Schneider, K; Weyerbrock, A	1
Date, I; Fujii, K; Ichikawa, T; Ishida, J; Kumon, H; Kurozumi, K; Nasu, Y; Oka, T; Onishi, M; Shimazu, Y; Watanabe, M	1
Ashby, L; Depenni, R; Fink, KL; Grujicic, D; Hegi, ME; Hicking, C; Lhermitte, B; Mazurkiewicz, M; Mikkelsen, T; Nabors, LB; Nam, DH; Perry, JR; Picard, M; Reardon, DA; Salacz, M; Tarnawski, R; Zagonel, V	1
Ahluwalia, MS; Batchelor, TT; Duda, DG; Gerstner, ER; Grossman, S; Jain, RK; Kaley, TJ; Levine, MA; Mikkelsen, T; Nabors, BL; Olson, JJ; Wen, PY; Ye, X	1
Bunse, L; Burghardt, I; Gramatzki, D; Hao, N; Leske, H; Platten, M; Roth, P; Rushing, EJ; Silginer, M; Weller, M	1
Lin, Q; Lu, CT; Mao, KL; Shen, XT; Tian, FR; Wong, HL; Xiao, J; Xu, HL; Xu, J; Yang, JJ; Yang, W; Zhao, YZ	1
Anderson, HJ; Galileo, DS	1
Date, I; Ichikawa, T; Ishida, J; Kurozumi, K; Shimizu, T	1
Gramatzki, D; Roth, P; Seystahl, K; Weller, M	1
Ding, L; Gao, L; Lv, P; Qi, L; Wang, S; Wang, W; Xu, Y; Zhao, D; Zhong, Y	1
Adams, B; Maurer, GD; Stupp, R; Tabatabai, G; Tritschler, I; Weller, M; Wick, W	1
Desideri, S; Fisher, J; Grossman, SA; Nabors, LB; Piantadosi, S; Rosenfeld, M; Ye, X	1
Clement, PM; Dietrich, PY; Diserens, AC; Goldbrunner, R; Grabenbauer, GG; Hegi, ME; Hermisson, M; Hicking, C; Krueger, S; Neyns, B; Ochsenbein, AF; Pica, A; Picard, M; Pietsch, T; Schlegel, U; Simon, M; Stupp, R; Tonn, JC; Weller, M	1
Carter, A	1
Stupp, R; Tabatabai, G	1
Chamberlain, MC	1
Chang, S; Cloughesy, T; Deangelis, LM; Gilbert, MR; Kuhn, J; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, M; Prados, M; Wen, PY	1
Brodie, C; Finniss, S; Jiang, W; Lee, HK; Lemke, N; Lomonaco, SL; Mikkelsen, T; Rempel, SA; Xiang, C	1
Bethe, U; Lansiaux, A; Le Tinier, F; Leblond, P; Meignan, S	1
Berti, F; Bertorelle, R; Della Puppa, A; Farina, M; Farina, P; Gardiman, MP; Lombardi, G; Polo, V; Zagonel, V; Zustovich, F	1
Batchelor, T; Brem, S; Fisher, JD; Grossman, SA; Hegi, ME; Lesser, G; Mikkelsen, T; Nabors, LB; Olsen, J; Peereboom, D; Rosenfeld, MR; Ye, X	1
Date, I; Fujii, K; Ichikawa, T; Kurozumi, K; Onishi, M	1
Caporello, P; Enrici, RM; Minniti, G; Scaringi, C	1
DeWitt, JP; Han, JH; Kim, B; Kim, CY; Kim, SK; Kim, YH; Lee, JE; Lee, JK; Oh, CW	1
Goodman, SL; Hasenbach, K; Maurer, G; Moch, H; Roth, P; Schraml, P; Silginer, M; Tabatabai, G; Thies, S; Tritschler, I; Weller, M	1
Dubowitz, DJ; Fraser, S; Gonzalez-Gomez, I; Jacobs, R; Khankaldyyan, V; Laug, WE; Moats, RA; Nelson, MD; Schultz, L; Taga, T; Velan-Mullan, S	1
Akella, NS; Cloud, GA; Grossman, S; Hochberg, FH; Mikkelsen, T; Nabors, LB; Twieg, DB	1
Sasaki, H; Yoshida, K	1
Akella, NS; Carson, K; Cloud, GA; Colevas, AD; Fisher, JD; Grossman, SA; Hochberg, F; Mikkelsen, T; Nabors, LB; Rosenfeld, SS; Wittemer, SM; Zhang, Y	1
Boyett, JM; Ellenbogen, RG; Goldman, S; Kieran, MW; Kocak, M; Kun, LE; Lafond, D; MacDonald, TJ; Phillips, P; Poussaint, TY; Stewart, CF	1
Cheresh, DA; Laug, WE; MacDonald, TJ; Shimada, H; Tabrizi, P; Taga, T; Zlokovic, BV	1
Barsky, L; Gilles, FH; Gonzalez-Gomez, I; Laug, WE; Shimada, H; Stins, M; Suzuki, A; Taga, T; Weinberg, KI	1

Reviews

13 review(s) available for cilengitide and Brain Neoplasms

Article	Year
Molecular biomarker-guided anti-angiogenic targeted therapy for malignant glioma. Journal of cellular and molecular medicine, 2019, Volume: 23, Issue:8 Topics: Angiogenesis Inhibitors; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Glioma; Humans; Indoles; Molecular Targeted Therapy; Prognosis; Snake Venoms	2019
Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme. Neurologia medico-chirurgica, 2013, Volume: 53, Issue:11 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Cell Adhesion; Combined Modality Therapy; Glioblastoma; Humans; Integrin alphaVbeta3; Neoplasm Invasiveness; Neoplasm Proteins; Neovascularization, Pathologic; Snake Venoms; Vascular Endothelial Growth Factor A	2013
Standards of care and novel approaches in the management of glioblastoma multiforme. Chinese journal of cancer, 2014, Volume: 33, Issue:1 Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Cancer Vaccines; Electric Stimulation Therapy; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Immunotherapy; Quinazolines; Snake Venoms; Standard of Care; Vaccines, Subunit	2014
Antiangiogenic therapy for high-grade glioma. The Cochrane database of systematic reviews, 2014, Sep-22, Issue:9 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Glioblastoma; Humans; Hypertension; Irinotecan; Lomustine; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Proteinuria; Randomized Controlled Trials as Topic; Snake Venoms; Temozolomide	2014
Adhesion molecules and the extracellular matrix as drug targets for glioma. Brain tumor pathology, 2016, Volume: 33, Issue:2 Topics: Angiogenesis Inhibitors; Antibodies; Brain Neoplasms; Cell Adhesion Molecules; Disease Progression; Extracellular Matrix; Glioma; Humans; Molecular Targeted Therapy; Neoplasm Invasiveness; Neovascularization, Pathologic; Snake Venoms; Thalidomide; White Matter	2016
Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives. Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:9 Topics: Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Neovascularization, Pathologic; Snake Venoms; Temozolomide	2016
A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT). Oncotarget, 2016, Oct-18, Volume: 7, Issue:42 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bayes Theorem; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Cisplatin; Dacarbazine; Disease-Free Survival; Eflornithine; Glioma; Humans; Mitolactol; Network Meta-Analysis; Nimustine; Probability; Randomized Controlled Trials as Topic; Snake Venoms; Temozolomide; Treatment Outcome; Vincristine	2016
[Angiogenesis inhibition in neurooncology. A very promising therapy strategy for malignant glioma]. Der Nervenarzt, 2010, Volume: 81, Issue:8 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Glioma; Humans; Microcirculation; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Snake Venoms; Vascular Endothelial Growth Factor A	2010
Angiogenesis and invasion in glioma. Brain tumor pathology, 2011, Volume: 28, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Disease Models, Animal; Endothelial Cells; Extracellular Matrix; Glioma; Humans; Mice; Molecular Targeted Therapy; Neoplasm Invasiveness; Neovascularization, Pathologic; Rats; Snake Venoms; Tenascin; Thalidomide	2011
Cilengitide in bevacizumab-refractory high-grade glioma: two case reports and critical review of the literature. Anti-cancer drugs, 2012, Volume: 23, Issue:7 Topics: Adult; Angiogenesis Inhibitors; Astrocytoma; Brain Neoplasms; Female; Glioma; Humans; Integrin alphaVbeta3; Male; Middle Aged; Platelet Membrane Glycoproteins; Salvage Therapy; Snake Venoms	2012
Cilengitide treatment for malignant glioma: current status and future direction. Neurologia medico-chirurgica, 2012, Volume: 52, Issue:8 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Integrins; Neoplasm Invasiveness; Snake Venoms	2012
Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. Anticancer research, 2012, Volume: 32, Issue:10 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Glioblastoma; Humans; Integrins; Mice; Rats; Signal Transduction; Snake Venoms; Temozolomide	2012
[Inhibition of cellular adhesion and invasion in gliomas]. Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 9 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cathepsin B; Cell Adhesion; Clinical Trials as Topic; Drug Design; Extracellular Matrix; Glioma; Humans; Hyaluronan Receptors; Hyaluronic Acid; Hydroxamic Acids; Integrins; Laminin; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Multigene Family; Neoplasm Invasiveness; Signal Transduction; Snake Venoms; Urokinase-Type Plasminogen Activator	2005

Trials

11 trial(s) available for cilengitide and Brain Neoplasms

Article	Year
Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group. Neuro-oncology, 2013, Volume: 15, Issue:10 Topics: Adolescent; Adult; Brain Neoplasms; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glioma; Humans; Infant; Male; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Snake Venoms; Survival Rate; Tissue Distribution; Young Adult	2013
Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. Journal of neuro-oncology, 2014, Volume: 117, Issue:1 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Snake Venoms; Temozolomide; Treatment Outcome	2014
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. The Lancet. Oncology, 2014, Volume: 15, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Confidence Intervals; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Administration Schedule; Early Detection of Cancer; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Promoter Regions, Genetic; Proportional Hazards Models; Reference Values; Snake Venoms; Survival Analysis; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins	2014
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro-oncology, 2015, Volume: 17, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Promoter Regions, Genetic; Snake Venoms; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins	2015
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. Neuro-oncology, 2015, Volume: 17, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioblastoma; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Snake Venoms; Treatment Outcome; Young Adult	2015
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jun-01, Volume: 28, Issue:16 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Combined Modality Therapy; Confidence Intervals; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Immunohistochemistry; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neurosurgical Procedures; Probability; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Risk Assessment; Snake Venoms; Survival Analysis; Temozolomide; Treatment Outcome	2010
Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. Journal of neuro-oncology, 2012, Volume: 106, Issue:1 Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Disease-Free Survival; Endpoint Determination; Female; Glioblastoma; Humans; Immunotherapy; Integrins; Karnofsky Performance Status; Male; Middle Aged; Recurrence; Snake Venoms	2012
A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer, 2012, Nov-15, Volume: 118, Issue:22 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Integrins; Male; Middle Aged; Snake Venoms; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult	2012
Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial. Journal of magnetic resonance imaging : JMRI, 2004, Volume: 20, Issue:6 Topics: Angiogenesis Inhibitors; Blood Flow Velocity; Blood Volume; Brain Neoplasms; Disease Progression; Echo-Planar Imaging; Glioblastoma; Glioma; Humans; Magnetic Resonance Angiography; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Peptides, Cyclic; Snake Venoms	2004
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13 Topics: Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Glioma; Humans; Magnetic Resonance Imaging; Maximum Tolerated Dose; Recurrence; Snake Venoms	2007
Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Feb-20, Volume: 26, Issue:6 Topics: Adolescent; Adult; Angiogenesis Inhibitors; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Female; Genotype; Humans; Infant; Infusions, Intravenous; Magnetic Resonance Imaging; Male; Snake Venoms; Treatment Outcome	2008

Other Studies

24 other study(ies) available for cilengitide and Brain Neoplasms

Article	Year
Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report. CNS oncology, 2023, 06-01, Volume: 12, Issue:2 Topics: Brain Neoplasms; Child; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Prognosis; Temozolomide	2023
Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma. Cancer cell, 2017, Dec-11, Volume: 32, Issue:6 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Gene Expression Profiling; Glioblastoma; Glucose Transporter Type 3; Humans; Integrin alphaVbeta3; Kaplan-Meier Estimate; Mice; Mice, Nude; Signal Transduction; Snake Venoms; Transcriptome; Xenograft Model Antitumor Assays	2017
[Cilengitide]. Nihon rinsho. Japanese journal of clinical medicine, 2016, Volume: 74 Suppl 7 Topics: Brain Neoplasms; Humans; Snake Venoms	2016
Novel Integrin αvβ3-Specific Ligand for the Sensitive Diagnosis of Glioblastoma. Molecular pharmaceutics, 2019, 09-03, Volume: 16, Issue:9 Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Gene Knockout Techniques; Glioblastoma; Human Umbilical Vein Endothelial Cells; Humans; Integrin alphaVbeta3; Ligands; Male; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Oligopeptides; Optical Imaging; Protein Binding; Snake Venoms; Transfection; Xenograft Model Antitumor Assays	2019
The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus. Cancer gene therapy, 2013, Volume: 20, Issue:8 Topics: Angiogenic Proteins; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Chlorocebus aethiops; Combined Modality Therapy; Glioma; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Peptide Fragments; Receptors, G-Protein-Coupled; Snake Venoms; Vero Cells; Xenograft Model Antitumor Assays	2013
In vitro study of combined cilengitide and radiation treatment in breast cancer cell lines. Radiation oncology (London, England), 2013, Oct-23, Volume: 8 Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Female; Gene Expression Regulation, Neoplastic; Humans; Integrin beta Chains; Integrin beta3; Neoplasm Metastasis; Snake Venoms	2013
Differential growth inhibition of cerebral metastases by anti-angiogenic compounds. Anticancer research, 2014, Volume: 34, Issue:7 Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor; Combined Modality Therapy; Female; Genetic Therapy; Interleukin-12; Melanoma; Mice; Mice, Nude; Peptides, Cyclic; Snake Venoms; Transfection	2014
Cilengitide in glioblastoma: when did it fail? The Lancet. Oncology, 2014, Volume: 15, Issue:10 Topics: Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Snake Venoms; Temozolomide; Tumor Suppressor Proteins	2014
Lack of evidence for PlGF mediating the tumor resistance after anti-angiogenic therapy in malignant gliomas. Journal of neuro-oncology, 2015, Volume: 121, Issue:2 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Brain; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Endothelial Cells; Glioma; Humans; Middle Aged; Neoplasm Grading; Placenta Growth Factor; Pregnancy Proteins; Prognosis; Retrospective Studies; RNA, Messenger; Snake Venoms; Vascular Endothelial Growth Factor Receptor-1	2015
Integrin antagonist augments the therapeutic effect of adenovirus-mediated REIC/Dkk-3 gene therapy for malignant glioma. Gene therapy, 2015, Volume: 22, Issue:2 Topics: Adaptor Proteins, Signal Transducing; Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Caspase 8; Caspase 9; Cell Line, Tumor; Chemokines; Combined Modality Therapy; Female; Gene Knockdown Techniques; Genetic Therapy; Glioma; Humans; Integrins; Intercellular Signaling Peptides and Proteins; Mice, Inbred BALB C; Mice, Nude; Peptides, Cyclic; Snake Venoms; Transduction, Genetic; Xenograft Model Antitumor Assays	2015
The aryl hydrocarbon receptor links integrin signaling to the TGF-β pathway. Oncogene, 2016, 06-23, Volume: 35, Issue:25 Topics: Animals; Animals, Newborn; Antibodies, Neutralizing; Brain Neoplasms; Cell Line, Tumor; Cells, Cultured; Glioblastoma; Hepatocytes; Humans; Immunoblotting; Immunohistochemistry; Integrins; Mice, Inbred C57BL; Mice, Knockout; Naphthyridines; Peptides, Cyclic; Receptors, Aryl Hydrocarbon; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Snake Venoms; Sulfonamides; Transforming Growth Factor beta	2016
Glioma-targeted therapy using Cilengitide nanoparticles combined with UTMD enhanced delivery. Journal of controlled release : official journal of the Controlled Release Society, 2016, Feb-28, Volume: 224 Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Survival; Drug Delivery Systems; Glioma; Heparin; Male; Microbubbles; Nanoparticles; Neoplasm Proteins; Poloxamer; Rats; Rats, Sprague-Dawley; Snake Venoms; Survival Analysis; Tissue Distribution; Ultrasonics	2016
Small-molecule inhibitors of FGFR, integrins and FAK selectively decrease L1CAM-stimulated glioblastoma cell motility and proliferation. Cellular oncology (Dordrecht), 2016, Volume: 39, Issue:3 Topics: Aniline Compounds; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Focal Adhesion Kinase 1; Glioblastoma; Humans; Integrin alphaVbeta3; Neural Cell Adhesion Molecule L1; Pyrimidines; Receptors, Fibroblast Growth Factor; Receptors, Vitronectin; Snake Venoms	2016
Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro-oncology, 2009, Volume: 11, Issue:6 Topics: Animals; Antineoplastic Agents, Alkylating; bcl-X Protein; Brain Neoplasms; Cell Adhesion; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; DNA Methylation; Drug Therapy, Combination; Gene Silencing; Glioma; Humans; Immunoblotting; In Vitro Techniques; Integrin alphaVbeta3; Mice; Neoplasm Invasiveness; NIH 3T3 Cells; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Receptors, Vitronectin; Snake Venoms; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2009
Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Apr-15, Volume: 16, Issue:8 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Benzodiazepines; Biomedical Research; Brain Neoplasms; Carboxymethylcellulose Sodium; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Drug Therapy, Combination; Female; Glioblastoma; Humans; Interferon Inducers; Male; Middle Aged; Poly I-C; Polylysine; Receptors, AMPA; Snake Venoms; Survival Rate; Temozolomide; Treatment Outcome; United States; Young Adult	2010
Integrins as target: first phase III trial launches, but questions remain. Journal of the National Cancer Institute, 2010, May-19, Volume: 102, Issue:10 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Glioblastoma; Humans; Integrins; Neoplasms; Snake Venoms	2010
What role should cilengitide have in the treatment of glioblastoma? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-20, Volume: 28, Issue:33 Topics: Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblastoma; Humans; Snake Venoms; Temozolomide	2010
Cilengitide induces autophagy-mediated cell death in glioma cells. Neuro-oncology, 2011, Volume: 13, Issue:8 Topics: Animals; Autophagy; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Gamma Rays; Glioma; Humans; Neoplastic Stem Cells; Radiation-Sensitizing Agents; Rats; Rats, Nude; Snake Venoms; Transplantation, Heterologous	2011
[The inhibitor of integrins Cilengitide: a new active drug in neuro-oncology]. Bulletin du cancer, 2011, Volume: 98, Issue:9 Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Extracellular Matrix; Humans; Integrin alphaVbeta3; Integrins; Molecular Targeted Therapy; Receptors, Vitronectin; Snake Venoms	2011
Combination therapy of cilengitide with belotecan against experimental glioblastoma. International journal of cancer, 2013, Aug-01, Volume: 133, Issue:3 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Glioblastoma; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Snake Venoms; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays	2013
Integrin control of the transforming growth factor-β pathway in glioblastoma. Brain : a journal of neurology, 2013, Volume: 136, Issue:Pt 2 Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Integrins; Mice; Mice, Nude; Mink; Neural Pathways; Snake Venoms; Transforming Growth Factor beta1	2013
Micro-MRI at 11.7 T of a murine brain tumor model using delayed contrast enhancement. Molecular imaging, 2003, Volume: 2, Issue:3 Topics: Anatomy, Cross-Sectional; Animals; Brain Neoplasms; Cell Line, Tumor; Contrast Media; Feasibility Studies; Female; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Injections, Intraperitoneal; Integrins; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Peptides, Cyclic; Radiographic Image Enhancement; Snake Venoms; Time Factors; Transplantation, Heterologous	2003
Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery, 2001, Volume: 48, Issue:1 Topics: Allantois; Angiogenesis Inhibitors; Animals; Blood Vessels; Brain Neoplasms; Chick Embryo; Chorion; Drug Resistance; Humans; Integrins; Mice; Mice, Nude; Neoplasm Transplantation; Peptides, Cyclic; Skin Neoplasms; Snake Venoms; Transplantation, Heterologous	2001
alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. International journal of cancer, 2002, Apr-10, Volume: 98, Issue:5 Topics: Animals; Apoptosis; Brain Neoplasms; Cell Adhesion; Cell Division; Collagen; Flow Cytometry; Fluorescent Antibody Technique; Glioblastoma; Humans; Immunoenzyme Techniques; In Situ Nick-End Labeling; Integrins; Medulloblastoma; Mice; Mice, Nude; Peptides, Cyclic; Receptors, Vitronectin; Snake Venoms; Tenascin; Tumor Cells, Cultured; Vitronectin	2002